Retatrutide Titration (TRIUMPH Research Protocol)
Safety Advisory
Due to the glucagon component, heart rate monitoring is often noted in study protocols. Nausea risk is dose-dependent.
Protocol Description
TRIUMPH trial protocol. Month 1: 2.0mg weekly. Month 2: 4.0mg weekly. Month 3: 6.0mg (optional maintenance). Month 4: 9.0mg. Month 5: 12.0mg (Max).
Community Logs
0 VERIFIED ENTRIESNo logs recorded for this protocol yet.
Be the first to contribute data.